National Cancer Institute

U.S. National Institutes of Health | www.cancer.gov

Introduction

The National Cancer Institute (NCI) and the [COOP GROUP NAME] have developed a **brief online survey** tool to quickly and easily solicit comments from oncologists and research staff in the field about specific NCI clinical **trials that have low accrual rates**.

We would like your opinions about the [TRIAL NAME] ([TRIAL DESCRIPTION]).

Your comments will help NCI and the [COOP GROUP NAME] to decide how to move forward with the [TRIAL NAME] trial and possible ways to increase its accrual and reach its projected goals. We thank you for your assistance!

To continue and begin the survey, click the "Next" button below.

Next-->

If you experience any technical difficulties, please contact the survey administrator at User-Centered Design at survey@user-centereddesign.com

National Cancer Institute

U.S. National Institutes of Health | www.cancer.gov

Privacy Statement and Consent

Your participation in this survey is completely voluntary. Please be assured that your participation in the survey is anonymous and your responses cannot be linked or associated with you.

You may skip any questions that you prefer not to answer. You are also free to stop participating at any point during the survey and have your responses deleted by clicking the "Opt out of survey" box at the bottom of each survey page.

This brief survey should only require approximately 1 minute of your time.


Please click the "Next" button if you consent to taking this survey.

Opt out of survey

Next -->

Public reporting burden for this collection of information is estimated to average 1 minute per response including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 208927974, ATTN: PRA (0000-0000-00). Do not return the completed form to this address.

If you experience any technical difficulties, please contact the survey administrator at User-Centered Design at survey@user-centereddesign.com



National Cancer Institute	U.S. National Institutes of Health www.cancer.gov
Please reply to all questions from the perspective of <u>your</u> site	a.
Please indicate which best describes your site:	
My practice is located within an academic medical cer	nter
My practice is located within an NCI-Designated Cano	
My practice is located within a community hospital (i.e.	
IWe are a free-standing private practice	
Other:	
1a. What best describes the size of your community hospi	ital compared to others?
 We are a small-size community hospital (less than 	100 beds)
 We are a mid-size community hospital (between 10 	4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
 We are a large-size community hospital (more than 	250 beds)
Please indicate which best describes your site's affiliation	(s): (Please check all that apply)
CCOP	
MB-CCOP	
NCCCP	
ALLIANCE	
□ ECOG-ACRIN	
SWOG	
□ RTOG-NSABP-GOG	
□ COG	
□ EORTC	
COGNO (Cancer Australia)	
□ NCIC	
☐ Other:	
Which category best describes your role at your practice?	
Physician	
Staff member/other	
Opt out of survey	Save and Continue>
If you experience any technical difficulties, ple at User-Centered Design at surveyor	

Note: Q1a appears only if "My practice is located within a community hospital" is selected for Q1.

If user selects "physician" to Q3, continue below. If user selects "Staff member/other", continue <u>HERE</u>.

National Cancer Institute	U.S. National Institutes of Health www.cancer.gov
4. What type of oncology best describes your expertise? Medical oncology Surgical oncology Radiation oncology Gynecologic oncology Pediatric oncology	
○ [VARIABLE] ○ Other:	
Opt out of survey	Save and Continue>
If you experience any technical difficulties, please conta at User-Centered Design at survey@user-cent	

XXXX National (Cancer Institute		U.S. National Institutes of Heal	th www.cancer.gov
The [TRIAL NAME interesting it is to you] trial has [INSERT #] rese	arch question[s]. [Fo	reach,] Please tell us how	scientifically
RQ1: [INSERT RO	1 FROM CONCEPT SHE	ET]		
5a1. How scien	tifically interesting is this re	esearch question to v	ou?	
Not at all	,	,	Very	
interesting			interesting	
0	0 0	0		
5a2. Which stat	ement best matches your o	opinion?		
 RQ1 is more 	interesting to me than wh	en it first opened.		
RQ1 is less	interesting to me than whe	en it first opened.		
	it the same level interest to	me as when it first o	pened.	
Please elaborat	he.			
T TOUGO GIADOTA				
RQ2: [INSERT RO	22 FROM CONCEPT SHE	ET]		
Fh4 Hawasian	##!!!-!#!		2	
Not at all	tifically interesting is this re	esearch question to y		
interesting			Very interesting	
0	0 0	0	0	
5h2 Which stat	ement best matches your o	oninion?		
obe. Willow out	omone book matorico your c	pinion.		
 RQ2 is more 	interesting to me than wh	en it first opened.		
RQ2 is less	interesting to me than whe	en it first opened.		
	it the same level interest to	me as when it first o	pened.	
Please elabora	in'			
Fiedse elabora				
Opt out of survey				Save and Continue>
	If you experience any technic	al difficulties, please conta	ct the survey administrator	

your treatment of	ILWIENI II	LEIL			
Limited impact				High impact	
0	0	0	0	0	
How much do you	u agree or disa	gree with this s	statement?		
The potential be conduct it at my		trial for patient	ts are worth th	ne effort and resource	es required to open an
Strongly Disagree				Strongly Agree	
ACCOUNT OF THE PARTY OF THE PAR	0	0	0	-	
Disagree			d you make to	-	ME] trial with respect

9. For each of the trial's requirements listed below, please tell us whether of to open or run the [TRIAL NAME] trial at your site.		es of Health wo	
How difficult does (or would) this requirement make it to open or run this trial at your site?	Not make it difficult to open/ run the trial	Make it somewhat difficult to open/ run the trial	Make it yery difficult to open/run the trial
[INSERT ITEM 1 FROM TRIAL SUMMARY SHEET]	0	0	0
[INSERT ITEM 2 FROM TRIAL SUMMARY SHEET]	0		0
[INSERT ITEM 3 FROM TRIAL SUMMARY SHEET]	0	0	0
[INSERT ITEM N FROM TRIAL SUMMARY SHEET]	0	0	
Opt out of survey	nou administrat		nd Continue>

at User-Centered Design at survey@user-centereddesign.com


Mational Cancer Institute U.S. National Institutes of Health | www.cancer.gov 10. How often do you see a patient who may be eligible for the [TRIAL NAME] trial (i.e., [PATIENT TYPE])? Daily Weekly Monthly Every few months A couple times per year or less 11. Which specialty at your institution would most likely be in the position to recommend or refer this trial to a potentially eligible patient? Medical oncology Surgical oncology Radiation oncology Gynecologic oncology Pediatric oncology [VARIABLE] Other (please specify): Opt out of survey Save and Continue --> If you experience any technical difficulties, please contact the survey administrator at User-Centered Design at survey@user-centereddesign.com

Opt out of survey

How difficult does (or would) this issue make it to accrue patients to this trial?	Not make it difficult to accrue patients to the trial	Make it somewhat difficult to accrue patients to the trial	Make it very difficult to accrue patients to the trial
Burden on patient to participate in the trial (e.g., logistics, time)	0	0	0
Inclusion/exclusion criteria of the study	0	0	0
Patients declining to enroll (e.g., unwilling to randomize, prefer one study arm)	0	0	0
Explaining the trial's details to a patient, including consenting	0	0	0
Getting patients referred to the trial	0		0
Cost to the patient (e.g., insurance, reimbursement)	0		0

If you experience any technical difficulties, please contact the survey administrator at User-Centered Design at survey@user-centereddesign.com

Save and Continue -->



If user selects "Yes" to Q14, continue below. If user selects "No", continue HERE.

s only)	en at your site?	AL NAME] trial?
I. //E] trial to ope	_	
ME] trial to ope	_	
	_	
0	0	Very difficult
0	0	
		0
imited burden enses ogist(s) in the p rch question(s encer t patient popu	on staff or coopractice	al at your site? [Select up to 3.] ordination, have equipment needed)
		Save and Continue
	enses ogist(s) in the properties of the patient popular, logistics, cos	enses ogist(s) in the practice rch question(s)

	National Cancer Institute	U.S. National Institutes of Health www.cancer.gov
18. Do	you have any final comments about the [TRIAL NAME]	trial that you would like to share?
Opt out	of survey	Submit Survey>
	If you experience any technical difficulties, please at User-Centered Design at survey@use	

凝凝	National	Cancer Institute	U.S. National Institutes of Health www.cancer.gov
Survey	Complete		
		Thank you for co	ompleting this survey!
		Your answers have be	en submitted anonymously.
	Your comm		regarding the [TRIAL NAME] trial.
	If you wo		after the survey closes, please send an email to ab@mail.nih.gov
		You may now	close this window.
			Ities, please contact the survey administrator survey@user-centereddesign.com

National Cancer Institute	U.S. National Institutes of Health www.cancer.gov
13. How many similar trials are open at your site that comp NAME] trial?	pete for the same patient population as the [TRIAL
Number of similar trials open a	
# competing trials that are sponsored by NCI (incli	uding cooperative group trials)
# competing trials that are sponsored by pharmace	eutical/biotech industry
# competing trials that are investigator initiated trial	als from academic medical centers
14. Has your site opened the [TRIAL NAME] trial? O Yes No	Save and Continue —
Opt out of survey	Save and Continue —
If you experience any technical difficulties, at User-Centered Design at surve	

MILLIE HACIONAL	Cancer Ins	stitute		U.S. National Institutes of Health www.cancer.gov
5. Given what you our site?	read in the <u>tria</u>	I summary shee	t, how interes	ed are you in opening the [TRIAL NAME] trial a
Not at all interested				Very interested
0	0	0	0	0
6. What are the top Not scientifically Does not match of Limited interest to	interesting en our patient por	ough	ened the [TRIA	L NAME] trial?
Not scientifically Does not match of Limited interest to Too many competed from the	interesting en our patient pop our patient pop eting trials for t urden on patier onduct the stud our site would ccrue patients	ough pulation his cancer hts (e.g., logistic ly (e.g., burden of be too great (e.g., randomiza	s, cost) on staff, coord g., non-reimb	L NAME] trial? Ination required, equipment needed) ursable expenses) g many to identify one; anticipate high refusals)
Not scientifically Does not match of Limited interest to Too many composition Too great of a but Too difficult to confine Financial cost to Too difficult to act Too difficult to act Too difficult to act Too difficult to act	interesting en our patient pop our patient pop eting trials for t urden on patier onduct the stud our site would ccrue patients	ough pulation his cancer hts (e.g., logistic ly (e.g., burden of be too great (e.g., randomiza	s, cost) on staff, coord g., non-reimb	ination required, equipment needed) ursable expenses)

	National Cancer Institute	U.S. National Institutes of Health www.cancer.gov
17. Do	you have any final comments about the [TRIAL NAME] trial t	that you would like to share?
Ont out	of survey	Submit Survey>
- Spe out	If you experience any technical difficulties, please contact at User-Centered Design at survey@user-cent	

類類	National	Cancer Institute	U.S. National Institutes of Health www.cancer.gov
urvey	Complete		
		Thank you for co	empleting this survey!
		Your answers have be	en submitted anonymously.
	Your comm		regarding the [TRIAL NAME] trial. ve forward to address the trial's accrual challenges.
	If you wo	경기 위한 경기 경기 가입니다. 그 경기 가입니다 그 경기 가입니다. 그리고 있는 것이 없는데 그 없는데 없었다.	after the survey closes, please send an email to ab@mail.nih.gov
		You may now	close this window.
			lties, please contact the survey administrator survey@user-centereddesign.com

National Cancer Institute	U.S. National Institutes of Health www.cancer.gov
Please reply to all questions from the perspective of your site	0.
Please indicate which best describes your site:	
My practice is located within an academic medical ce	nter
My practice is located within an NCI-Designated Cand	
 My practice is located within a community hospital (i.e 	
I/We are a free-standing private practice	
Other:	
1a. What best describes the size of your community hosp	ital compared to others?
 We are a small-size community hospital (less than 	100 beds)
 We are a mid-size community hospital (between 10 	
 We are a large-size community hospital (more than 	250 beds)
2. Please indicate which best describes your site's affiliation	(s): (Please check all that apply)
□ CCOP	
□ NCCCP	
□ ALLIANCE	
☐ ECOG-ACRIN	
☐ SWOG	
☐ RTOG-NSABP-GOG	
□ COG	
□ EORTC	
COGNO (Cancer Australia)	
□ NCIC	
Other:	
Which category best describes your role at your practice?	
○ Physician	
Staff member/other	
Opt out of survey	Save and Continue
If you experience any technical difficulties, ple	area combact the current administrator

Note: Q1a appears only if "My practice is located within a community hospital" is selected for Q1.

National Cancer Institute	U.S. National Institutes of Health www.cancer.gov
S1. What category best describes your role within your practice? (Se	elect one)
Research Nurse	
Site Administrator / Manager	
○ Coordinator	
○ CRA (non-nurse)	
Regulatory Specialist	
○ Data Manager	
Other:	
Opt out of survey	Save and Continue>
If you experience any technical difficulties, please contac at User-Centered Design at <u>survey@user-cent</u>	

National Cancer Institute u.s. N	lational Institut	es of Health w	vw.cancer.gov			
ne [TRIAL NAME] trial was opened by the [COOP GROUP NAME] in [INSERT MONTH, YEAR]. To date, [INSERT #] trients have been accrued to the trial. We expected a significantly more robust accrual than we have experienced. As uch, NCI and [COOP GROUP NAME] are interested in learning from the field what issues are limiting accrual to [TRIAL AME] and possible ways to increase its accrual and reach its projected goals.						
S2. How much do you agree or disagree with this statement?						
The potential benefits of this trial for patients are worth the effort an conduct it at my site.	The potential benefits of this trial for patients are worth the effort and resources required to open and					
Strongly Strong Disagree Agree						
0 0 0 0						
How difficult does (or would) this requirement make it to open or run this trial at your site?	Not make it difficult to open/ run the trial	Make it somewhat difficult to open/ run the trial	Make it yery difficult to open/run the trial			
[INSERT ITEM 1 FROM TRIAL SUMMARY SHEET]	0	0	0			
[INSERT ITEM 2 FROM TRIAL SUMMARY SHEET]	0		0			
[INSERT ITEM 3 FROM TRIAL SUMMARY SHEET]	0	0	0			
[INSERT ITEM N FROM TRIAL SUMMARY SHEET]	0	0	0			
Opt out of survey If you experience any technical difficulties, please contact the sur			ubmit Survey>			


National C	ancer Ins	stitute		U.S. National Institute	s of Health www.cancer.gov
S4. How often does yo TYPE])?	our practice :	see patients who	o may be eligib	le for the [TRIAL NAM	E] trial (i.e., [PATIENT
○ Daily					
○Weekly					
MonthlyEvery few month	ns				
A couple times p		ess			
Do not know					
S5. Which specialty a potentially eligible pat		ion would most	likely be in the	position to recommen	d or refer this trial to a
 Medical oncolo 	gy				
 Surgical oncolo 					
Radiation oncoGynecologic on					
Pediatric oncole					
○ [VARIABLE]					
Other (please s	pecify):				
S6. Overall, how diffic	ult do you be	elieve the [TRIA	L NAME] trial w	vill be to open at your s	site?
Not at all difficult				Very difficult	
0	0		0	0	
Opt out of survey					Save and Continue>
				ontact the survey administrate centereddesign.com	or .

Opt out of survey

How difficult does (or would) this issue make it to accrue patients to this trial?	Not make it difficult to accrue patients to the trial	Make it somewhat difficult to accrue patients to the trial	Make it very difficult to accrue patients t the trial
Getting patients referred to the trial	0	0	0
Burden on patient to participate in the trial (e.g., logistics, time)	0	0	0
Patients declining to enroll (e.g., unwilling to randomize, prefer one study arm)	0	0	0
Inclusion/exclusion criteria of the study	0	0	0
Explaining the trial's details to a patient, including consenting	0	0	0
Cost to the patient (e.g., insurance, reimbursement)	0	0	0

If you experience any technical difficulties, please contact the survey administrator at User-Centered Design at survey@user-centereddesign.com

Save and Continue -->



If user selects "Yes" to QS9, continue below. Otherwise continue HERE.

National	Cancer Ins	stitute		U.S. National Institutes of Health www	cancer.gov
S10. To date, how r	many patients	has your site ac	crued to the [TF	IAL NAME] trial?	
(Number of	patients - integ	gers only)			
☐ My site has no	ot opened this	trial.			
S11. How difficult w	as the [TRIAL	NAME] trial to	open at your site	?	
Not at all difficult				Very difficult	
0	0	0	0	0	
Why?					
					_
					A

12. What were the	top reasons fo	or opening the [TRIAL NAME] t	ial at your site? [Select up to 3.]	
☐ Availability of	fatudu da ia/a\				
Ease in accru					
☐ Limited non-r		xpenses			
Few competi		115.1000 a 12.000 a			
High level of	interest by onc	cologist(s) in the	practice		
 Limited burde 	en on patient (e	e.g., logistics, co	ost)		
Ease of doing	the study (e.g	, limited burde	n on staff or coo	rdination, have equipment needed)	
	interesting res	earch question((s)		
 Scientifically 	and for all and	rent patient pop	ulation		
ScientificallyFills unmet n	eed for our cur	our ponour pop			
	eed for our cur				
Fills unmet n	eed for our cur			Save and	d Continue —

	National Cancer Institute	U.S. National Institutes of Health www.cancer.gov
S13. D	o you have any final comments about the [TRIAL NAME] tri	al that you would like to share?
Opt out	of survey	Submit Survey>
	If you experience any technical difficulties, please contr at User-Centered Design at <u>survey@user-cer</u>	

National Cancer Institute	U.S. National Institutes of Health www.cancer.gov
urvey Complete	
Thank you for comple	ting this survey!
Your answers have been su	bmitted anonymously.
We appreciate your feedback regar Your comments will help us decide how to move for	4 1 N C.
If you would like a summary of the findings after to 61164thflrlab@m	아들아이라 교통이를 내용하면 되었다. 이 아이라지 않는 아이를 하는데 아이가 아니라 아이는 이 때 남아들이 보고 있는데 이 글 사람이 아니라
You may now close	this window.
If you experience any technical difficulties, ple at User-Centered Design at <u>survey</u>	

National Cancer Institute	U.S. National Institutes of Health www.cancer.gov
S8. How many similar trials are open at your site th NAME] trial?	nat compete for the same patient population as the [TRIAL
	open at your site from each sponsor (Integers only)
# competing trials that are sponsored by N	CI (including cooperative group trials)
# competing trials that are sponsored by pl	harmaceutical/biotech industry
# competing trials that are investigator initi	ated trials from academic medical centers
S9. Has your site opened the [TRIAL NAME] trial? O Yes No	
Opt out of survey	Save and Continue —
	ifficulties, please contact the survey administrator on at survey@user-centereddesign.com

National Cancer Institute				U.S. National Institutes of Health www.cancer.gov		
10. Given what yo t your site?	ou read in the trial	summary shee	et, how intere	sted are you in opening the [TRIAL NAM	/IE] trial	
Not at all interested				Very interested		
0	0	0	0	©		
Not scientifically Does not match	op reasons your s y interesting enoug our patient popula	gh ation	ened the [TR	AL NAME] trial?		
Not scientifically Does not match Limited interest Too many comp Too great of a b Too difficult to c Financial cost to	y interesting enough our patient popular by oncologist(s) he peting trials for this urden on patients onduct the study (o our site would be	gh ation here s cancer (e.g., logistics (e.g., burden o e too great (e.g.	s, cost) n staff, coord g., non-reimb	nation required, equipment needed) ursable expenses) g many to identify one; anticipate high re	fusals)	

	National Cancer Institute	U.S. National Institutes of Health www.cancer.gov
S12. D	o you have any final comments about the [TRIAL NAME] tri	al that you would like to share?
Opt out	of survey	Submit Survey>
	If you experience any technical difficulties, please cont at User-Centered Design at <u>survey@user-ce</u> r	

National Cancer Institute	U.S. National Institutes of Health www.cancer.gov
urvey Complete	
Thank you for comple	ting this survey!
Your answers have been su	bmitted anonymously.
We appreciate your feedback regar Your comments will help us decide how to move for	4 1 N C.
If you would like a summary of the findings after to 61164thflrlab@m	아들아이라 교통이를 내용하면 되었다. 이 아이라지 않는 아이를 하는데 아이가 아니라 아이는 이 때 남아들이 보고 있는데 이 글 사람이 아니라
You may now close	this window.
If you experience any technical difficulties, ple at User-Centered Design at <u>survey</u>	